Evaluating the Efficacy and Safety of a Unani formulation in Melasma.
Phase 2
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2023/10/059114
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Participants of any gender in the age group of 18-60 years.
Participants having bilateral symmetrical or asymmetrical brown macules on face (nose, forehead, upper lip and cheeks & chin ).
Participants who are willing to participate and comply with the protocol and to sign IEC approved ICF.
Exclusion Criteria
Participants aged <18 years and >60 years of age
Pregnant or Lactating Women
Mentally retarded person
Known allergy, sensitivity or intolerance to the study drug or any of its ingredients
Known case of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 25 % reduction in MASI Score from baselineTimepoint: 8 Weeks
- Secondary Outcome Measures
Name Time Method Melasma Quality of LifeTimepoint: 8 Weeks